An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis
Latest Information Update: 16 Dec 2023
At a glance
- Drugs Solcitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 26 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 03 Mar 2014 Status changed from recruiting to suspended, as reported by a Galapagos media release.
- 16 Jan 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.